Douglas C. Wolf

7.7k citations

209 papers · 5.8k indexed · 1 hit paper · h-index 42

Health, Toxicology and Mutagenesis top 0.5%
Molecular Biology top 5%
Cancer Research top 1%
Genetics top 2%
Immunology top 5%

Co-authors: Thomas L. Goldsworthy Jeffrey I. Everitt Susan Hester Michael H. George Tanya Moore Sheau‐Fung Thai Stephen Nesnow Amber K. Goetz
Topics: Carcinogens and Genotoxicity Assessment (38 papers)Inflammatory Bowel Disease (30 papers)Microscopic Colitis (16 papers)
Cited by: Chemical Health and Safety Health, Toxicology and Mutagenesis Cancer Research
Journals: Science New England Journal of MedicineSHILAP Revista de lepidopterología
Partner nations: United States United Kingdom Canada

In The Last Decade

Douglas C. Wolf

204 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

2016 360 citations Douglas C. Wolf, Geert D’Haens et al. profile →

Peers

Countries citing papers authored by Douglas C. Wolf

Since Specialization

Citations

This map shows the geographic impact of Douglas C. Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas C. Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas C. Wolf more than expected).

Fields of papers citing papers by Douglas C. Wolf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas C. Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas C. Wolf. The network helps show where Douglas C. Wolf may publish in the future.

Co-authorship network of co-authors of Douglas C. Wolf

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas C. Wolf. A scholar is included among the top collaborators of Douglas C. Wolf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas C. Wolf. Douglas C. Wolf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension 2023 ·Journal of Crohn s and Colitis ·(unknown),Silvio Danese,Douglas C. Wolf,James B. Canavan,(unknown),(unknown),(unknown),Lorna Charles,(unknown),María T. Abreu	3
2	P50 A phase 1/2 randomized, placebo-controlled, multiple ascending dose study (ACHIEVE) of DYNE-101 in individuals with myotonic dystrophy type 1 (DM1) 2023 ·Neuromuscular Disorders ·Douglas C. Wolf,(unknown),Baoqin Han,A. Dugar,Wildon Farwell	1
3	P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy 2023 ·Journal of Crohn s and Colitis ·Geert D’Haens,Marla C. Dubinsky,Laurent Peyrin‐Biroulet,Silvio Danese,B E Sands,Douglas C. Wolf,Andrés Yarur,Michael Chiorean,(unknown),Irene Modesto,Huaming Tan,(unknown),(unknown),Chunyan Su,(unknown),Fabio Cataldi,(unknown),Stefanie Schreiber,B G Feagan,Séverine Vermeire	14
4	DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study 2023 ·Journal of Crohn s and Colitis ·Silvio Danese,María T. Abreu,Douglas C. Wolf,James B. Canavan,(unknown),(unknown),(unknown),Lorna Charles,(unknown),(unknown)	4
5	Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis 2022 ·Zeitschrift für Gastroenterologie ·Britta Siegmund,Silvio Danese,J.F. Colombel,Terry Ponich,Igor Jovanović,Patrick M. Bossuyt,Randy Longman,(unknown),(unknown),(unknown),Lorna Charles,DT Rubin,Anita Afzali,Edward V. Loftus,Douglas C. Wolf	2
6	An evaluation of carcinogenicity predictors from short-term and sub chronic repeat-dose studies of agrochemicals in rats: Opportunities to refine and reduce animal use 2021 ·Toxicology Letters ·Pratibha Mistry,Elizabeth F. McInnes,Carol Beevers,Douglas C. Wolf,A Currie,(unknown),(unknown)	3
7	An evaluation framework for new approach methodologies (NAMs) for human health safety assessment 2020 ·Regulatory Toxicology and Pharmacology ·Stanley T. Parish,Michael Aschner,Warren Casey,Marco Corvaro,Michelle R. Embry,Suzanne Fitzpatrick,Darren Kidd,Nicole Kleinstreuer,Beatriz Silva Lima,Raja S. Settivari,Douglas C. Wolf,Daiju Yamazaki,Alan R. Boobis	135
8	Chemical carcinogenicity revisited 3: Risk assessment of carcinogenic potential based on the current state of knowledge of carcinogenesis in humans 2019 ·Regulatory Toxicology and Pharmacology ·Samuel M. Cohen,Alan R. Boobis,Vicki L. Dellarco,John E. Doe,Penelope A. Fenner-Crisp,Angelo Moretto,Timothy P. Pastoor,Rita Schoeny,Jennifer Seed,Douglas C. Wolf	71
9	Effects of prenatal exposure to a low dose atrazine metabolite mixture on pubertal timing and prostate development of male Long-Evans rats 2010 ·Reproductive Toxicology ·Jason P. Stanko,(unknown),Jennifer L. Rayner,Christine Davis,Douglas C. Wolf,David E. Malarkey,Suzanne E. Fenton	41
10	Income and the Use of Prescription Drugs by the Elderly 2005 ·SSRN Electronic Journal ·John R. Moran,Kosali Simon,(unknown),Timothy M. Smeeding,(unknown),Douglas Holtz‐Eakin,Douglas C. Wolf,John Ýinger	0
11	Oxidative DNA damage from potassium bromate exposure in Long-Evans rats is not enhanced by a mixture of drinking water disinfection by-products 2005 ·Chemico-Biological Interactions ·Kevin S. McDorman,Brian F. Pachkowski,Jun Nakamura,Douglas C. Wolf,James A. Swenberg	27
12	Crohn's Colitis Presenting With Node-Negative Colon Cancer and Liver Metastasis After Therapy With Infliximab: Report of Two Cases 2005 ·Diseases of the Colon & Rectum ·(unknown),Guy R. Orangio,(unknown),Douglas C. Wolf,(unknown)	8
13	Labor induction in women with an unfavorable Bishop score: Randomized controlled trial of intrauterine Foley catheter with concurrent oxytocin infusion versus Foley catheter with extra-amniotic saline infusion with concurrent oxytocin infusion 2004 ·American Journal of Obstetrics and Gynecology ·Debra A. Guinn,Jill Davies,Richard O. Jones,Lisa Sullivan,Douglas C. Wolf	22
14	The transcriptional profile of the kidney in Tsc2 heterozygous mutant Long Evans (Eker) rats compared to wild-type 2004 ·Mutation research. Fundamental and molecular mechanisms of mutagenesis ·(unknown),Douglas C. Wolf,Susan Hester	8
15	Analysis of preneoplastic and neoplastic renal lesions in Tsc2 mutant Long–Evans (Eker) rats following exposure to a mixture of drinking water disinfection by-products 2003 ·Toxicology ·Kevin S. McDorman,Michelle J. Hooth,Thomas B. Starr,Douglas C. Wolf	13
16	Promotion by sodium barbital induces early development but does not increase the multiplicity of hereditary renal tumors in Eker rats 2000 ·Carcinogenesis ·Douglas C. Wolf,Thomas L. Goldsworthy,Derek B. Janszen,(unknown),Erica Donner,(unknown),Jeffrey I. Everitt	8
17	IBD Highlights from the 1999 American College of Gastroenterology Meeting: Infliximab and 6-MP 2000 ·Inflammatory Bowel Diseases ·Douglas C. Wolf	3
18	Methyl tertiary butyl ether lacks tumor-promoting activity in N-nitrosodiethylamine-initiated B6C3F1 female mouse liver 1996 ·Carcinogenesis ·Glenda J. Moser,Brian A. Wong,Douglas C. Wolf,Ronny Fransson-Steen,Thomas L. Goldsworthy	15
19	Absence of p53 gene mutations in rat colon carcinomas induced by azoxymethane 1995 ·Cancer Letters ·Narayan Shivapurkar,Steven A. Belinsky,Douglas C. Wolf,Zhaocheng Tang,Oliver Alabaster	27
20	Nasal Toxicity of Chloroform in Male F-344 Rats and Female B6C3F1 Mice Following a 1-Week Inhalation Exposure 1994 ·Toxicology and Applied Pharmacology ·(unknown),Jeffrey L. Larson,Byron E. Butterworth,Douglas C. Wolf,(unknown),Kevin T. Morgan	37

About Douglas C. Wolf

Douglas C. Wolf is a scholar working on Chemical Health and Safety, Cancer Research and Health, Toxicology and Mutagenesis, having authored 209 papers that have together received 5.8k indexed citations. Recurring topics across this work include Carcinogens and Genotoxicity Assessment (38 papers), Inflammatory Bowel Disease (30 papers) and Microscopic Colitis (16 papers). The work is most often cited by research in Chemical Health and Safety (92 citations), Health, Toxicology and Mutagenesis (1.6k citations) and Cancer Research (1.1k citations). Douglas C. Wolf has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Thomas L. Goldsworthy, Jeffrey I. Everitt, Susan Hester, Michael H. George, Tanya Moore, Sheau‐Fung Thai, Stephen Nesnow, Amber K. Goetz, Anthony B. DeAngelo and Byron E. Butterworth. Their work appears in journals such as Science, New England Journal of Medicine and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact